Cantabio Pharmaceuticals Inc. (CTBOD) financial statements (2020 and earlier)

Company profile

Business Address 2225 EAST BAYSHORE ROAD
PALO ALTO, CA 94303
State of Incorp. DE
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
TTM
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1093252 517
Cash and cash equivalents 1093252 517
Prepaid expense  1   
Prepaid expense and other current assets13
Total current assets: 1093452 529
Noncurrent Assets
Other undisclosed assets      1
TOTAL ASSETS: 1093452 530
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 60737822519714
Accrued liabilities 17114017319714
Other undisclosed accounts payable and accrued liabilities 43623852   
Debt 947322    
Due to related parties 25847239 1
Other undisclosed current liabilities 171140173   
Total current liabilities: 1,98388742227716
Noncurrent Liabilities
Total liabilities: 1,98388742227716
Stockholders' equity
Stockholders' equity attributable to parent (1,873)(854)(370)(27)(2)14
Common stock 522727554
Common stock, value, subscriptions 1,0601,060500 
Additional paid in capital 1,1351679911311344
Accumulated deficit (4,120)(2,108)(996)(146)(120)(34)
Total stockholders' equity: (1,873)(854)(370)(27)(2)14
TOTAL LIABILITIES AND EQUITY: 1093452 530

Income statement (P&L) ($ in thousands)

12/31/2018
TTM
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Gross profit:   (32)   
Operating expenses (2,327)(1,788)(1,533)(25)(87)(27)
Other undisclosed operating income     164
Operating loss: (2,327)(1,788)(1,565)(25)(87)(27)
Nonoperating income (expense) (628)25(18)   
Foreign currency transaction loss, before tax   (18)   
Debt instrument, convertible, beneficial conversion feature 3568    
Other nonoperating income (expense) (663)(43)0   
Interest and debt expense (861)(40)108   
Loss from continuing operations before income taxes: (3,816)(1,803)(1,475)(25)(87)(27)
Income tax expense (benefit) 257    (9)
Net loss: (3,559)(1,803)(1,475)(25)(87)(36)
Other undisclosed net income attributable to parent 1,547691724  9
Net loss available to common stockholders, diluted: (2,012)(1,112)(751)(25)(87)(27)

Comprehensive Income ($ in thousands)

12/31/2018
TTM
3/31/2018
3/31/2017
3/31/2016
3/31/2015
3/31/2014
3/31/2013
Net loss: (3,559)(1,803)(1,475)(25)(87)(36)
Comprehensive loss, net of tax, attributable to parent: (3,559)(1,803)(1,475)(25)(87)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: